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Acute Decompensation Boosts Hepatic
Collagen Type III Deposition and
Deteriorates Experimental and
Human Cirrhosis
Michael Praktiknjo,1* Jennifer Lehmann,1* Mette J. Nielsen,2,3* Robert Schierwagen,1 Frank E. Uschner,1 Carsten Meyer,4
Daniel Thomas,4 Christian P. Strassburg,1 Flemming Bendtsen,5 Søren Møller ,6 Aleksander Krag,3 Morten A. Karsdal,2
Diana J. Leeming,2** and Jonel Trebicka 1,3,7,8**
Patients with end-stage liver disease develop acute decompensation (AD) episodes, which become more frequent and
might develop into acute-on-chronic liver failure (ACLF). However, it remains unknown how AD induces acceleration
of liver disease. We hypothesized that remodeling of collagen type III plays a role in the acceleration of liver cirrhosis
after AD and analyzed its formation (Pro-C3) and degradation (matrix metalloproteinase-degraded type III collagen
[C3M]) markers in animal models and human disease. Bile duct ligation induced different stages of liver ﬁbrosis in
rats. Fibrosis development (hydroxyprolin content, sirius red staining, a-smooth muscle actin immunohistochemistry,
messenger RNA of proﬁbrotic cytokines), necroinﬂammation (aminotransferases levels), ﬁbrolysis (matrix metalloprotei-
nase 2 expression and activity, C1M, C4M), and Pro-C3 and C3M were analyzed 2, 3, 4, 5, and 6 weeks after bile
duct ligation (n 5 5 each group). In 110 patients with decompensated liver cirrhosis who underwent a transjugular
intrahepatic portosystemic shunt procedure for AD, clinical and laboratory parameters as well as Pro-C3 and C3M
were measured in blood samples from portal and hepatic veins and were collected just before the transjugular intrahe-
patic portosystemic shunt placement and 1-3 weeks later. Animal studies showed increased markers of collagen type III
deposition with ﬁbrosis, necroinﬂammation, and decompensation of liver cirrhosis, deﬁned as ascites development.
Higher Pro-C3 levels were associated with injury, disease severity scores (Model for End-Stage Liver Disease, Child-
Pugh, chronic liver failure-C AD), ACLF development, and mortality. C3M decreased with AD and the chronic liver
failure-C AD score. Collagen type III deposition ratio increased with the risk of ACLF development and
mortality. Conclusion: We show for the ﬁrst time that AD boosts collagen type III deposition in experimental and
human cirrhosis, possibly contributing to the worsened outcome in patients with decompensated cirrhosis. (Hepatology
Communications 2018;2:211-222)
Introduction
Chronic liver diseases are a growing health careburden. Liver cirrhosis is the common endstage of any chronic liver disease and can
decompensate with its progression.(1) Progressive
ﬁbrosis, increased hepatic vascular tone, and ongoing
inﬂammation due to permanent liver injury are major
causes of decompensation, morbidity, and mortality.
These processes incite continuous extracellular matrix
(ECM) protein remodeling, which reﬂects the pro-
gression of liver disease.(2-6) During ECM remodeling,
Abbreviations: a-SMA, a-smooth muscle actin; ACLF, acute-on-chronic liver failure; AD, acute decompensation; BDL, bile duct ligation; C3M,
metalloproteinase-degraded type III collagen; CLIF-C, chronic liver failure-C; ECM, extracellular matrix; MELD, Model for End-Stage Liver
Disease; MMP, matrix metalloproteinase; Pro-C3, formation of type III collagen; TIPS, transjugular intrahepatic portosystemic shunt.
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matrix metalloproteinases (MMPs) generate small
peptide fragments, known as neoepitopes, that are
released into the circulation. They can be measured
with protein ﬁngerprint technology using speciﬁc anti-
bodies.(7) The levels of these ECM markers depend on
the degree of ﬁbrosis(4,8-10) and also reﬂect antiﬁbrotic
therapy.(5,11) Degradation markers and collagen type
III formation, in particular, mirror progression of
ﬁbrosis and diagnosis of portal hypertension(4,10,12,13);
however, the roles of these markers in decompensation
of liver cirrhosis have not been assessed.
As outlined above, severe liver ﬁbrosis with portal
hypertension induces acute decompensation (AD),
such as variceal bleeding, refractory ascites, or hepa-
torenal syndrome, which can be treated with transjugu-
lar intrahepatic portosystemic shunt implantation
(TIPS).(14) In selected patients, TIPS decompresses
the portal venous system, successfully treats ascites and
variceal bleeding, and improves survival.(14-17) How-
ever, AD of liver cirrhosis can progress and develop
into acute-on-chronic liver failure (ACLF) with poor
survival.(18) While deposition of ECM in the course of
liver ﬁbrosis has been known for some time, the role of
collagen in patients with advanced liver cirrhosis and
AD(19) remains unclear.
The present work demonstrates for the ﬁrst time
that collagen III turnover markers show a speciﬁc pat-
tern in the course of progression of liver ﬁbrosis and
can predict development of ACLF and mortality in
patients with decompensated liver cirrhosis.
Materials and Methods
HUMAN STUDY DESIGN
We studied 110 patients with decompensated liver
cirrhosis who underwent a TIPS procedure between
1996 and 2003. Inclusion criteria were age between 20
and 80 years, cirrhosis due to alcohol or viral hepatitis,
and decompensated liver cirrhosis with indication for
TIPS (bleeding in n 5 41, refractory ascites in n 5 51,
or both in n 5 18). Exclusion criteria were contraindi-
cations for TIPS placement,(20,21) i.e., serum levels of
bilirubin >5 mg/dL, spontaneous bacterial peritonitis
and manifest hepatic encephalopathy, pulmonary arte-
rial hypertension, and cardiac insufﬁciency. An invasive
control of the TIPS was performed as part of the rou-
tine in 74 patients 1-3 weeks after TIPS insertion.(10)
Biochemical blood analyses were performed using stan-
dard tests. The local ethics committee of the University
of Bonn approved the study (029/13), and all patients
agreed and signed informed consent for the procedures
in accordance with the Helsinki Declaration.
TRANSJUGULAR INTRAHEPATIC
PORTOSYSTEMIC SHUNT
INSERTION AND HEMODYNAMIC
MEASUREMENTS
TIPS (8-10 mm Wallstent; Boston Scientiﬁc)
placement was performed as described.(20,21) A single
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shot of antibiotic prophylaxis of cefuroxime (1.5 g) was
administered at TIPS placement. Portal and hepatic
venous pressures were measured invasively using a
pressure transducer system (Combitrans; B. Braun
Melsungen, Melsungen, Germany) and a multichannel
monitor (Sirecust; Siemens). The difference between
portal and hepatic venous pressures was deﬁned as the
portal hepatic pressure gradient. Arterial pressure and
heart rate were monitored noninvasively. Biochemical
parameters as well as portal and systemic hemodynam-
ics were recorded. Blood from the portal and hepatic
veins was collected as described.(22) The blood sample
from the portal vein was taken immediately after punc-
ture of the vein. The hepatic venous sample was taken
from the hepatic vein, which was used for the creation
of TIPS, right before puncturing the portal vein. Portal
venous samples were taken immediately after entering
the portal vein but before dilation of the tract or inser-
tion of the TIPS stent. At invasive TIPS control after
a median of 10 days (range, 1-3 weeks), a catheter was
advanced into the portal vein. Blood from the portal
and hepatic veins was collected. Protein ﬁngerprint
markers were assessed in the portal and the hepatic
vein plasma samples.
ANIMAL STUDY DESIGN
Sprague-Dawley rats with an initial body weight of
180-200 g were used. Thirty rats underwent bile
duct ligation (BDL) to induce liver ﬁbrosis as
described.(23-25) A mortality of 20% led to a total of 24
rats for assessment. This study was authorized by the
local committee for animal studies (Bezirksregierung
K€oln, 50.203.2-BN22, 46/05). All rats received chow
and water ad libitum and were weighed and fed daily.
BDL rats were killed 2, 3, 4, 5, and 6 weeks after BDL
(n 5 5 per group, except for 4 weeks after BDL, n 5
4). Blood was withdrawn and liver samples were cut
into fragments and either snap frozen in liquid nitro-
gen and stored at –808C or preserved in formaldehyde
as described.(11,23,24)
PROTEIN FINGERPRINT MARKER
ASSESSMENT
MMP-degraded type III collagen (C3M)(9) and for-
mation of type III collagen (Pro-C3(26)) were exam-
ined. Additionally, MMP-degraded type I (C1M) and
type IV (C4M) collagen were measured.(10) Brieﬂy,
each assay was run on a 96-well streptavidin plate
coated with the appropriate biotinylated synthetic
peptide dissolved in an optimized assay and incubated
for 30 minutes at 208C. Next, 20 lL of calibrator pep-
tide or sample in appropriate dilution was added to the
wells, including 100 lL of horseradish peroxidase-
conjugated monoclonal antibody raised against the
speciﬁc sequence of interest and incubated for 1 hour
at 208C or overnight at 48C. Following incubation,
100 lL tetramethylbenzinidine (Kem-En-Tec cat.
4380H) was added, and the plate was incubated for 15
minutes at 208C in the dark. In order to stop the reac-
tion, 100 lL of stopping solution (1% H2SO4) was
added and measured at 450 nm with 650 nm as refer-
ence. All incubation steps included shaking at 300 rev-
olutions per minute. After coating and antibody
incubation, the plate was washed 5 times in washing
buffer (20 mM Tris, 50 mM NaCl, pH 7.2). A cali-
bration curve was plotted using a four-parametric ﬁt
model. Samples were measured within the detection
range.
HEPATIC HYDROXYPROLINE
CONTENT
Hepatic hydroxyproline was photometrically deter-
mined in liver hydrolysates.(23,24) Segments (200 mg)
of snap-frozen livers were hydrolyzed in HCl (6 N) at
1108C for 16 hours and ﬁltered. Aliquots (50 lL)
from each sample were incubated with chloramine T
(2.5 mM) for 5 minutes and Ehrlich’s reagent (410
mM) for 30 minutes at 608C. Absorption was mea-
sured 3 times at 558 nm. For determination of
hydroxyproline concentration, a standard curve for
hydroxyproline was used. Results are expressed as
micrograms per gram of wet liver tissue.
SIRIUS RED STAINING,
a-SMOOTH MUSCLE ACTIN
IMMUNOHISTOCHEMISTRY, AND
MORPHOMETRY
Liver specimens were ﬁxed in 10% formalin. As
described,(23) parafﬁn-embedded sections (2-3 lm)
were stained in 0.1% sirius red F3B in saturated picric
acid (Chroma, M€unster, Germany) to detect collagen
ﬁbers. For immunohistochemical staining of a-smooth
muscle actin (a-SMA), sections were incubated with a
mouse-anti-a-SMA antibody (clone 1A4; Sigma-
Aldrich, St. Louis, MO) diluted 1:600 in Tris-
buffered saline for 60 minutes. A biotinylated rabbit-
anti-mouse antibody absorbed with rat serum (Dako,
Glostrup, Denmark) was used as secondary antibody
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and subsequently applied, diluted 1:200, for 45
minutes. Next, streptavidin-conjugated alkaline phos-
phatase (1:200, 45 minutes; Dako) was attached to the
complex. Finally, sections were developed with new
fuchsin-naphtol AS-BI (Sigma-Aldrich) and counter-
stained with hematoxylin. Stereomicroscopic analysis
was performed as described.(23) On sections with a
surface of 1 cm2, 500 points were counted at 4003
magniﬁcation. On sirius red staining, test points were
classiﬁed as connective tissue (positive staining),
hepatocytes, bile ducts, or other structures (not
stained). a-SMA-positive cells were counted on a-
SMA-immunohistologic sections and characterized by
their location as sinusoidal, periductular, portal/septal,
and others (e.g., vascular smooth muscle cells). The
volume fraction of each structure was calculated as per-
centage of points overlaying the structure in relation to
the total number of counted points.
QUANTITATIVE REVERSE-
TRANSCRIPTION POLYMERASE
CHAIN REACTION OF
CONNECTIVE TISSUE GROWTH
FACTOR, PLATELET-DERIVED
GROWTH FACTOR, AND
TRANSFORMING GROWTH
FACTOR BETA 1
RNA was isolated from 30-mg liver segments, using
the RNeasy kit (Qiagen, Basel, Switzerland) with
deoxyribonuclease treatment (Promega, Wallisellen,
Switzerland), followed by reverse transcription with
Moloney murine leukemia virus reverse transcriptase
(Invitrogen, Basel, Switzerland) according to the man-
ufacturer’s instructions. Quantitative polymerase chain
reaction was carried out on an ABI 7700 sequence
detector (Applied Biosystems, Rotkreuz, Switzerland)
with described sequences and accession numbers.(23)
Gene expression values were calculated based on the
DCt method(23,25) and normalized to expression of
glyceraldehyde 3-phosphate dehydrogenase. Results
were calculated as 2–DCt to express the fold increase of
gene expression compared to sham-operated rats.
MMP-2 ZYMOGRAPHY
Proteolytic activity of tissue homogenates was exam-
ined by gelatin zymography as published.(23) The
supernatants of liver homogenates (20 lg of protein)
were subjected to 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis using gels contain-
ing 0.3% gelatin. Proteolytic bands of 62 and 65 kDa,
corresponding to the active and latent form of
MMP-2, respectively, were quantiﬁed by densitometry
using AIDA software (Raytest, Urdorf, Switzerland).
STATISTICAL ANALYSIS
Plasma levels of the four protein ﬁngerprint markers
(Pro-C3 and C3M; C1M and C4M) were logarithmi-
cally transformed to obtain normality and symmetry of
variance. All correlations were calculated using Spear-
man’s correlation. Comparison of the levels of protein
ﬁngerprints assessed in portal and hepatic venous
blood at baseline and at the control visit were analyzed
using the paired-samples t test. Patient survival was
calculated by Kaplan-Meier analysis, while survival
curves were compared using the log-rank test. Univari-
ate and multivariate analyses of patients’ characteristics
as predictors of mortality were calculated by Cox
regression analysis. All data are shown as median with
95% conﬁdence interval (CI) or as mean 6 SEM. Dif-
ferences between curves were calculated using two-way
analysis of variance. P < 0.05 was considered statisti-
cally signiﬁcant. Statistical analyses were performed
using SPSS 23 (IBM, Armonk, NY). Data were plot-
ted using GraphPad Prism v.5 (Graph Pad Software,
La Jolla, CA).
Results
PATIENT CHARACTERISTICS
The study population included 110 patients with
cirrhosis, of whom 71 (64.5 %) were male individuals.
The median age was 59 (36-80) years. Etiology of cir-
rhosis was alcoholic liver cirrhosis in 81 (73.6%)
patients, chronic viral hepatitis C in 13 (11.8%)
patients, while 16 (14.6%) patients had other causes,
including 11 (10%) patients with cryptogenic cirrhosis,
3 patients with primary biliary cirrhosis, and 2 patients
suffering from autoimmune hepatitis. Median Model
for End-Stage Liver Disease (MELD) score was
8 (6-18) and Child-Turcotte-Pugh score was 8 (5-12).
Before TIPS implantation, most patients showed
esophageal varices (I-II8, 65.6%; III-IV8, 20.9%) and
ascites (mild, 26.4%; severe, 46.4%). Hepatorenal syn-
drome was present in 25.5% of patients. The general
characteristics and laboratory values of the study popu-
lation are summarized in Tables 1 and 2.
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COLLAGEN TYPE III
REMODELING MARKERS
BEFORE AND AFTER TIPS
The levels of formation marker Pro-C3 in the
hepatic vein were signiﬁcantly higher than in the portal
vein before and at a median of 10 days after TIPS
placement (Fig. 1A,B), suggesting the liver to be the
main origin of these markers. Interestingly, a compari-
son between the levels of the degradation marker C3M
from the portal and the hepatic vein showed a similar
difference but without reaching statistical signiﬁcance
after TIPS (Fig. 1A,B). Of note, when comparing lev-
els of Pro-C3 and C3M from the same compartment
(hepatic or portal vein, respectively), both increased
signiﬁcantly after TIPS placement (Fig. 1C,D). These
data raise the question as to whether this increase is
due to mechanical liver parenchyma damage through
TIPS placement or whether it reﬂects a true remodel-
ing of collagen type III. Therefore, the time depen-
dency of the levels of these markers after TIPS was
analyzed (Fig. 1E,F). Importantly, after TIPS, levels of
Pro-C3 (Fig. 1F) and C3M (Fig. 1E) did not change
signiﬁcantly with time (8, 9-11, >11 days), sugges-
ting that mechanical liver injury is not involved in this
increase.
COLLAGEN TYPE III FORMATION
MARKER Pro-C3 AND SURVIVAL
As with previous observations(4,10,12,13) in patients
with liver ﬁbrosis and/or compensated liver cirrhosis,
patients with high Pro-C3 levels had a poorer outcome
than patients with lower levels (Fig. 2A). The cutoff to
discriminate between these two groups was set at 20
ng/mL in the hepatic vein (30 out of 110 patients),
which represents the thirty-third percentile.
COLLAGEN TYPE III FORMATION
MARKER Pro-C3 LEVELS ARE
INCREASED IN HEPATORENAL
SYNDROME
Patients with previous episodes of hepatorenal syn-
drome (HRS), which indicates severely impaired renal
function, had signiﬁcantly higher Pro-C3 levels in the
hepatic vein (Fig. 2B). Interestingly, collagen type III
degradation marker C3M levels did not differ between
the groups with and without previous HRS.
COLLAGEN TYPE III FORMATION
MARKER Pro-C3 LEVELS ARE
INCREASED IN PATIENTS WITH
ASCITES, WHILE COLLAGEN
TYPE III DEGRADATION MARKER
C3M LEVELS ARE DECREASED
In patients with no or mild (i.e., treatable with diu-
retics) ascites, Pro-C3 levels were signiﬁcantly lower
compared to patients with severe (refractory) ascites,
indicating increased collagen type III formation.
Inversely, we found C3M levels to be signiﬁcantly
decreased in patients with severe ascites compared to
TABLE 1. CLINICAL PARAMETERS OF ALL
PATIENTS (N 5 110) AT ADMISSION
Parameters Value
Sex (male/female) 71/39
Age (years) 59 (36-80)
Etiology of cirrhosis (alcoholic/chronic
viral hepatitis C/other)
81/13/16
Indication for TIPS implementation
(bleeding/ascites/both)
41/51/18
Child-Pugh score 8 (5-12)
Child-Pugh category (A/B/C) 17/67/26
MELD score 8 (6-18)
Varices (esophageal: absent/8I-II/8III-IV/gastric varices) 12/72/23/3
Variceal bleeding (absent/present) 51/59
Ascites (absent/mild/severe) 20/39/51
Hepatorenal syndrome (absent/type I/type II) 82/22/6
Hepatic encephalopathy (absent/history of) 98/12
Data are shown as median and ranges for continuous variables or
total number for categorical variables.
TABLE 2. PRESSURE GRADIENT AND
LABORATORY PARAMETERS OF PATIENTS AT
ADMISSION AND OUTCOME
Parameters
At TIPS
(n 5 110)
Control Visit
(n 5 74)
PSPG (mm Hg) 20 (11-35) 9 (2-21)‡
Bilirubin (mg/dL) 1.2 (0.3-14.8) 1.4 (0.55-10.4)‡
gGT (IU/L) 52 (8-527) 96 (12-515)‡
AST (IU/L) 19 (8-73) 22 (12-275)*
ALT (IU/L) 18 (4-94) 21 (4-357)‡
INR 1.2 (0.93-2.23) 1.2 (0.96-1.92)‡
Sodium (mEq/L) 135 (119-145) 136 (118-144)*
Platelet count (109/L) 105 (27-385) 122 (46-326)
Creatinine (mg/dL) 1.1 (0.5-8.2) 1.0 (0.5-7.1)†
BUN (mg/dL) 44 (9-225) 32 (1.14-118)‡
Data are shown as median and ranges. *P < 0.05, †P < 0.01,
‡P < 0.001.
Abbreviations: ALT, alanine transaminase; AST, aspartate trans-
aminase; BUN, blood urea nitrogen; gGT, gamma glutamyl
transpeptidase; INR, international normalized ratio; PSPG, portal
systemic pressure gradient.
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those with mild or no ascites, indicating decreased col-
lagen type III degradation at the same time (Fig. 2C).
COLLAGEN TYPE III TURNOVER
MARKERS AND PROGNOSTIC
SCORES
Patients with a MELD score of 11 or higher had
signiﬁcantly higher levels of Pro-C3 before TIPS com-
pared to those with lower MELD scores. Levels of
C3M, however, did not differ between the high and
low MELD groups (Fig. 2D). A similar picture was
observed in patients with Child-Pugh stage C, who
also had signiﬁcantly higher Pro-C3 levels before
TIPS compared to patients with Child-Pugh stages A
or B, while C3M levels were not statistically different
(Fig. 2E). As this possibly suggests promoted collagen
type III formation in patients with more advanced liver
cirrhosis, we calculated Pro-C3 and C3M levels in the
hepatic vein according to MELD and Child-Pugh
scores. As shown in Fig. 2F, levels of Pro-C3 continu-
ally increased with increasing MELD and Child-Pugh
scores, reﬂecting decompensated states of liver cirrho-
sis, while levels of C3M did not congruently increase
but instead did not change signiﬁcantly.
ANIMAL STUDIES
To further investigate whether there are any mecha-
nistic implications from the ﬁndings from our patient
samples, we conducted animal studies as described
above. These are summarized in Fig. 3A. In this
model, we observed histologically increasing stages of
ﬁbrosis with increasing time after BDL, as shown by
sirius red and a-SMA staining (Supporting Fig. S1).
CORRELATION OF PROFIBROTIC
CYTOKINES AND
NECROINFLAMMATION
Along with progression of liver ﬁbrosis, we could
also observe increasing necroinﬂammation with
increasing levels of aspartate aminotransferase and ala-
nine aminotransferase. Proﬁbrotic cytokines connective
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FIG. 1. Evolution of levels of Pro-C3 and C3M before and after TIPS. (A) Before the TIPS procedure, levels of Pro-C3 and C3M
were signiﬁcantly higher in the hepatic vein compared to the portal vein (P < 0.05). (B) After TIPS, Pro-C3 levels were signiﬁcantly
higher in the hepatic vein compared to the portal vein (P < 0.05), while the difference for C3M did not reach statistical signiﬁcance.
A signiﬁcant increase in Pro-C3 and C3M levels after the TIPS procedure was demonstrated in (C) for the hepatic vein and (D) for
the portal vein (P < 0.001). (E) C3M and (F) Pro-C3 levels over time after TIPS (<8, 9-11, and >11 days) as they did not change
signiﬁcantly (P > 0.05). *P < 0.05, **P < 0.01, ***P < 0.001; data represent mean 6 SEM. Abbreviation: n.s., not signiﬁcant.
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tissue growth factor, platelet-derived growth factor,
and transforming growth factor b1 showed a positive
correlation with alanine aminotransferase and aspartate
aminotransferase levels as markers of necroinﬂamma-
tion (Supporting Fig. S2A).
DYNAMICS OF COLLAGEN TYPE
III TURNOVER MARKERS
Pro-C3 levels signiﬁcantly increased continuously
with increasing time after BDL, which equates to
more advanced ﬁbrosis (Fig. 3B). Interestingly, the
accompanying levels of C3M remained unchanged
with advanced ﬁbrosis, even in decompensated states,
which began 4 and 5 weeks after BDL when the ani-
mals developed ascites (Fig. 3B). Statistical analysis
revealed the two curves (Pro-C3 and C3M) to diverge
signiﬁcantly (Fig. 3C). Because liver ﬁbrosis is an accu-
mulation of ECM, we normalized Pro-C3 and C3M
levels for hydroxyproline content (Fig. 3D). This
revealed that levels of C3M per each microgram of
hydroxyproline decrease with increasing severity of
liver ﬁbrosis. In contrast, Pro-C3 levels per each
microgram of hydroxyproline remained stable with
increasing severity of liver ﬁbrosis (Fig. 3D). Impor-
tantly, the curves of Pro-C3 and C3M again diverged
signiﬁcantly, suggesting a progressive net collagen
type III deposition due to increased formation and
decreased degradation with advanced and decompen-
sated liver ﬁbrosis (Fig. 3E).
CORRELATION OF FIBROSIS,
MMP2 ACTIVITY, AND
COLLAGEN TYPES I, III, AND IV
DEGRADATION
As expected, with increasing stages of ﬁbrosis, we
could show increasing ECM deposition in sirius red
staining with a strong correlation with a-SMA-
positive staining as a marker of hepatic stellate cell acti-
vation. Overall, MMP2 increased with progression of
ﬁbrosis. More importantly, MMP2 activity increased.
However, there was a negative correlation of C1M,
C3M, and C4M (normalized for hydroxyproline
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FIG. 2. Pro-C3 and C3M levels in the hepatic vein and their relationship with severity of human cirrhosis. (A) Kaplan-Meier stratiﬁed for
Pro-C3 levels at a threshold of 20 ng/mL in the hepatic vein. (B) Pro-C3 and C3M levels in the hepatic vein in patients with and without pre-
vious episodes of HRS. (C-E) Higher Pro-C3 levels in the hepatic vein and lower levels of C3M in patients with (C) severe ascites. Higher
Pro-C3 levels in patients with (D) higher MELD score (<11) and (E) Child-Pugh C score, while C3M levels did not change signiﬁcantly. (F)
Distribution of Pro-C3 and C3M levels according to MELD and Child-Pugh scores. A signiﬁcant divergence of Pro-C3 and C3M curves is
demonstrated. *P< 0.05, **P< 0.01, ***P< 0.001; data represent mean6 SEM. Abbreviation: n.s., not signiﬁcant.
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content of the liver) with sirius red staining, suggesting
decreased collagen degradation in advanced ﬁbrosis
(Supporting Fig. S2B). Of note, C3M showed the
strongest correlation with sirius red staining, sugges-
ting that degradation of collagen type III, in particular,
is impacted in advanced liver ﬁbrosis (Supporting Fig.
S2B). Interestingly, C1M only weakly correlated with
C3M and C4M, while C3M and C4M strongly corre-
lated with each other and with MMP2 activity.
COLLAGEN TYPE III DEPOSITION
RATIO (Pro-C3/C3M) IS
INDEPENDENT OF THE
TIPS PROCEDURE
Because the absolute values of Pro-C3 and C3M
failed to estimate collagen type III deposition in the
liver, we calculated the ratio of collagen type III forma-
tion and degradation markers Pro-C3 and C3M (Pro-
C3/C3M), assuming that this ratio reﬂects net produc-
tion and therefore deposition of collagen type III.
Importantly, we observed a higher net deposition ratio
in the hepatic vein than in the portal vein before and
after TIPS (data not shown). There was no signiﬁcant
change in the deposition ratio during the observed
time after TIPS (8, 9-11, and >11 days; data not
shown), which suggests that while TIPS placement
itself does not impact deposition ratio, in some patients
an increased deposition ratio after TIPS can be found.
This would also suggest that changes in the rate of liver
perfusion after TIPS have a mild effect on serum levels
of collagen type III markers.
COLLAGEN TYPE III DEPOSITION
RATIO (Pro-C3/C3M) IS
INCREASED IN PATIENTS WITH
HRS AND SEVERE ASCITES
We observed a signiﬁcantly higher deposition ratio
in patients with HRS (Fig. 4A). Accordingly, we also
found a signiﬁcantly higher deposition ratio in patients
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FIG. 3. Levels of Pro-C3 and C3M with severity of experimental ﬁbrosis in BDL-rats. (A) Experimental design of the rodent studies
with sacriﬁce at 5 different time points, T1-3 representing early stages of ﬁbrosis, T4-5 representing decompensated ﬁbrosis of the
liver. (B) Levels of Pro-C3 and C3M at different time points of sacriﬁce. Pro-C3 increased signiﬁcantly in severe stages of ﬁbrosis.
C3M did not change signiﬁcantly. (C) Signiﬁcant divergence of levels of Pro-C3 and C3M with increasing severity of ﬁbrosis. (D)
Levels of Pro-C3 and C3M at different time points of sacriﬁce normalized for hydroxyproline content per gram of liver tissue. C3M
decreased signiﬁcantly in severe stages of ﬁbrosis. Pro-C3 did not change signiﬁcantly. (E) Signiﬁcant divergence of levels of Pro-C3
and C3M with increasing severity of ﬁbrosis. The area between the curves represents net collagen type III deposition in the liver
(shaded area). *P < 0.05, **P < 0.01, ***P < 0.001; data represent mean 6 SEM. Abbreviation: ns, not signiﬁcant.
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with severe ascites compared to patients with or with-
out mild ascites (Fig. 4B).
COLLAGEN TYPE III DEPOSITION
RATIO (Pro-C3/C3M) INCREASED
WITH ACUTE DECOMPENSATION
AND MORTALITY
After stratifying the deposition ratio for prognostic
scores, we found a signiﬁcantly higher ratio for patients
with higher MELD and Child-Pugh scores (Fig. 4C).
Indeed, patients with higher chronic liver failure-C
(CLIF-C) AD score, reﬂecting a high risk of
ACLF,(27) also had a higher deposition ratio (Fig.
4D). Likewise, a higher deposition ratio was signiﬁ-
cantly associated with a higher CLIF-C AD score
(Fig. 4D) and with survival as shown in a Kaplan-
Meier plot using a ratio cutoff of 1.5 (ﬁftieth percen-
tile) (Fig. 4F). However, multivariate analysis did not
reveal a collagen type III deposition ratio as an inde-
pendent predictor for survival.
Discussion
This study demonstrates for the ﬁrst time that acute
decompensation boosts collagen type III net deposition
in the liver and that it possibly induces aggravation of
liver disease leading to ACLF with increased mortality.
Continuous liver injury leads to ECM remodeling in
response to tissue injury and to development of pro-
gressive ﬁbrosis in affected patients.(28-31) Develop-
ment of ascites and acute decompensation are decisive
events in patients with liver cirrhosis. From that
moment onward, patients are at a much higher risk of
developing further decompensation and face a higher
mortality. To date, little is known about the hepatic
pathophysiologic processes after the ﬁrst decompensa-
tion. One could speculate that ﬁbrosis is already pre-
sent and that the main pathophysiologic processes are
systemic inﬂammation and extrahepatic complications.
However, our study in animal models of biliary cirrho-
sis clearly shows that the development of ascites boosts
collagen type III deposition in the liver. This was not
only associated with increased formation, similar to the
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FIG. 4. Pro-C3/C3M ratio and disease severity in TIPS patients. (A) Signiﬁcantly higher Pro-C3/C3M ratio in patients with HRS.
(B) Signiﬁcantly higher Pro-C3/C3M ratio in patients with severe ascites. (C) Patients with MELD score >11 and Child-Pugh C
show a signiﬁcantly higher Pro-C3/C3M ratio. (D) Signiﬁcantly higher Pro-C3/C3M ratio in patients with CLIF-C AD score
>49.5, and patients with Pro-C3-/C3M ratio >1.5 show signiﬁcantly higher CLIF-C AD scores. (E) Signiﬁcant correlation of Pro-
C3/C3M ratio with ACLF. (F) Kaplan-Meier stratiﬁed for Pro-C3/C3M ratio at a threshold of 1.5 in the hepatic vein. *P < 0.05,
**P < 0.01, ***P < 0.001; data represent mean 6 SEM.
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general ECM proteins, but also associated with
decreased degradation of this speciﬁc collagen type.
This was also conﬁrmed in our TIPS patients.
Besides the animal data directly comparing the solu-
ble and indirect but noninvasive markers of liver ﬁbro-
sis, we have previously shown that patients with
compensated chronic liver disease show increased col-
lagen type III turnover, i.e., formation and degrada-
tion.(4,26) Interestingly, not only the formation marker
Pro-C3 but also the degradation marker C3M is corre-
lated with increased liver ﬁbrosis in human immuno-
deﬁciency virus /hepatitis C virus coinfected patients
with early liver disease as well as in another cohort
with compensated advanced liver disease.(4,10) The
present work conﬁrms these ﬁndings in the animal
model, demonstrating the robustness of these markers.
However, patients receiving TIPS have already experi-
enced AD. While Pro-C3 correlates with the progres-
sion of disease and decompensating events, such as
HRS, the degradation marker C3M levels decreased
with a higher risk of ACLF development as indicated
by the CLIF-C AD score.(30) This underlines what
the animal model data had suggested, namely that deg-
radation of collagen type III is attenuated in patients
with acute decompensation.
Interestingly, the increase of Pro-C3 serum levels
after TIPS and higher levels of Pro-C3 in more
advanced ﬁbrosis were consistent. This was also the
case in patients who experienced decompensation. At
ﬁrst glance, this seems to be contradictory. Our study
reveals that the increase in Pro-C3 in all patients after
TIPS insertion might be due to an increase in collagen
type III synthesis associated with deterioration of liver
function with changes in liver perfusion after TIPS.
This has been shown several times by us and other
studies.(4,22,32,33) However, the cutoff for survival ben-
eﬁt is much lower than the cutoff for the discrimina-
tion of developing acute decompensation in patients
receiving TIPS. Moreover, acute decompensation is
more strongly associated with the ratio between forma-
tion and degradation of collagen type III than just with
Pro-C3 levels.
We could also clearly demonstrate a correlation
between net collagen type III deposition with advanc-
ing chronic liver disease and acute decompensation in
rodent animal studies. Because we initially showed a
signiﬁcant increase in Pro-C3 levels without signiﬁcant
changes in C3M levels, whether the net collagen depo-
sition results predominantly from increased collagen
type III formation or decreased degradation remains to
be studied in future projects. However, when
normalized for hepatic hydroxyproline content, which
represents the entire ECM deposition and therefore
general ﬁbrosis, we found a signiﬁcant decrease in
C3M levels.
Our data possibly explain why in about half of the
patients in the CLIF Acute-on-Chronic Liver Failure
in Cirrhosis (CANONIC) study, no precipitating
event was determined for development of ACLF. One
hypothesis is that acute decompensation itself leads to
enhanced and uncontrolled collagen type III deposi-
tion, deterioration of liver injury, and thereby induc-
tion of ACLF (Fig. 4F). One pathophysiologic
explanation, suggested by this study, is that a massive
deposition of ECM in the liver diminishes the last
reserve of liver function, resulting in organ failure and
ACLF with a poor outcome. Further studies with
quantiﬁcation of collagen type III deposition are war-
ranted to conﬁrm this hypothesis.
Both collagen type III turnover markers (Pro-C3
and C3M) have been found in the urine of patients
with kidney ﬁbrosis.(34) Nevertheless, the exact route
of elimination remains unknown. Of note, the net col-
lagen type III deposition in our cohort was especially
pronounced with signiﬁcant renal dysfunction, a hall-
mark of ACLF development in Western countries as
well as the CANONIC cohort. One might expect
accumulation of these soluble fragments in renal dys-
function (as they are cleared through the kidney),(34)
but in fact C3M levels were lower in patients with
severe renal dysfunction, as determined by very low
sodium urinary excretion. Based on these consider-
ations, interpretation of our experimental and human
data suggests that AD boosts collagen type III deposi-
tion through decreased degradation, possibly repre-
senting one of the mechanisms by which the ﬁrst acute
decompensation deteriorates outcome.
Although this study has a well-characterized patient
cohort backed by rodent experimental data, it has sev-
eral limitations. While all samples were obtained pro-
spectively, data collection and measurements were
carried out retrospectively. However, we could rule out
change over time of these markers in previous experi-
ments. Also, the patients received a bare metal stent to
create TIPS, which is no longer the current standard
of care. Yet, the latter might be an advantage because
at the time this routine included an invasive control of
TIPS 1-3 weeks later, thus enabling the collection of
follow-up samples. Also, high pro-C3 levels possibly
reﬂect a higher degree of ﬁbrosis rather than an inde-
pendent factor as our multivariate analysis did not
reveal Pro-C3 to be an independent predictor for
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survival. However, we observed increasing formation
markers whereas degradation markers did not increase
in the same way. This suggests collagen deposition in
acute decompensation. The investigation of the exact
mechanism as to why collagen type III degradation
seems to be strongly associated with acute decompen-
sation compared to collagen type I and IV degradation
goes beyond the scope of this study. This hypothesis
and any related mechanisms require further conﬁrma-
tion in the future. Finally, the patients did not receive
liver biopsies in order to assess the deposition of colla-
gen type III.
In summary, this study shows for the ﬁrst time that
markers for collagen type III formation increase while
markers of degradation decrease with acute decompen-
sation and development of ACLF, reﬂecting mortality
in decompensated cirrhosis. Moreover, our study
might offer a novel precipitating event in the develop-
ment of ACLF, namely the boost of deposition of
ECM in the liver due to acute decompensation and
systemic inﬂammation, which eventually diminishes
the last reserve of liver function, resulting in organ fail-
ure and ACLF with a poor outcome.
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